Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$18.30+$0.3300 (+1.84%) on the dayAs of the close; data may be delayed.
SNDX price, last 12 months
Key stats
- Previous close
- $17.97
- Open
- $18.03
- Day range
- $17.77 – $18.35
- 52-week range
- $12.99 – $25.59
- Volume
- 1.1M
- Avg volume (20 days)
- 1.8M
- Market cap
- $1.6B
Performance
1W+3.9%
1M−8.9%
3M−14.1%
6M−25.9%
YTD−12.9%
1Y+21.9%
vs S&P 500, 1Y+5.1 pts
Technicals and fundamentals
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.6B